First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

By J. Soria, D. Tan, R. Chiari, Yi-long Wu, L. Paz-Ares, J. Wolf, Sarayut Lucien Geater, S. Orlov, D. Cortinovis, Chong-Jen Yu and 12 more. The Lancet, 2017

1,012 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0ea7da7b4061cf6001225afbeed4b22961418d0c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann

Citations in the corpus

• Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer (2017, neutral): “ALT increased 45 (30) 22 (15) 23 (15) 7 (5)”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “The ASCEND-4 trial compared ceritinib (750 mg/day) with platinum-based ChT (cisplatin or carboplatin plus pemetrexed followed by maintenance pemetrexed) in untreated advanced ALK-rearranged non-squamous NSCLC [200].”